

***Magnesium sulfate, as an alternative to sildenafil in
treatment of persistent pulmonary hypertension of
the new born in Egypt***

Thesis

Submitted in the Partial Fulfillment of M.Sc. Degree in Pediatrics

By

Lamiaa Mohammed Abdel Motelb

MBBCH

Faculty of Medicine

Cairo University

Under supervision of

Prof. Dr. Mohamed Fawzan Shaltout

Professor of Pediatrics

Faculty of Medicine

Cairo University

Prof. Dr. Hanna Aboulghar

Assistant Professor of Pediatrics

Faculty of Medicine

Cairo University

Prof. Dr. Rania Ali Hegazy

Lecture of Pediatrics

Faculty of Medicine

Cairo University

Faculty of Medicine

Cairo University

2009

Abstract

Persistent pulmonary hypertension of the newborn (PPHN), it is characterized by failure of the normal postnatal fall in pulmonary vascular resistance, it can cause both immediate and long term complication.

There are various modalities for treatment of PPHN. ECMO & INO are effective in treatment of PPHN but not available in developing countries.

Our study was done to light the comparison between the effects of oral sildenafil and magnesium sulfate in the treatment of PPHN.

Our study is prospective cohort review included 20 neonates. The neonates were divided into two groups: the first group represented 10 neonates treated with sildenafil, whereas the second group represented 10 neonates treated with magnesium sulfate. We found a statistically significant difference (P value 0,014) in estimated pulmonary artery pressure after another 3 days of treatment by sildenafil or magnesium sulfate. We also revealed that good improvement in Sao2&ABG with two groups but earlier in sildenafil group. Limited side effects and good outcome was observed in both groups.

Conclusion: we concluded that $MgSO_4$ can be used as an alternative treatment to sildenafil in treatment of PPHN in Egypt.

Keywords: Persistent pulmonary hypertension of the newborn (PPHN), sildenafil, Magnesium sulfate ($MgSO_4$).

Acknowledgement

A word of thanks to **Allah**, the source of all knowledge, by whose abundant grace, this work has come to life.

I feel like showing my greatest and deepest appreciation to the most generous, kind and patient team, I have got the honor to work with.

I wish to express my appreciation and sincere gratitude to **Prof. Dr. Mohamed Fawzan Shaltot, *Professor of Pediatrics, Faculty of Medicine, Cairo University***, for his kind help, indispensable advice and encouragement from the start of this work.

I would like to express my deep everlasting gratitude to **Dr. Hanna Aboulghar, *Professor of Pediatrics, Cairo University***, for her supervision, fruitful advice and for her constant valuable guidance and for her effort in the presentation of this work.

I am very grateful to **Dr. Rania Ali Hegazy *Professor of Pediatrics, Cairo University***, not only for her kind assistance and support, but also for her fruitful advice, constant valuable guidance.

Last but not least, I would like to thank all the staff members of the pediatrics department in **Kasr El-Aini University Hospital & Ahmed Maher Teaching hospital** for their help, support and cooperation especially **Dr. Ziad Mohi El Din, *the head of neonatology unit in Ahmed Maher teaching hospital*** who provides me with care, support and knowledge.

Contents

	Page
• List of tables.....	I
• List of figures.....	II – III
• List of abbreviations.....	IV– VI
• Introduction.....	1-2
• Aim of Work.....	3
• Review of literature	
Chapter 1: Anatomy & Physiology of pulmonary arterial vascular.....	4-23
Chapter 2: PPHN.....	24-50
Chapter 3: Treatment of PPHN.....	51-76
Chapter 4: Sildenafil & Magnesium sulfate.....	77-87
• Patients and Methods.....	88-95
• Results.....	96-107
• Discussion.....	108- 111
• Conclusion and Recommendation.....	112
• Summary.....	113
• References.....	114- 133
• Arabic Summary.....	134

List of Tables

No.	Title	Page
1	Neonatal conditions that may interfere with normal maturation of pulmonary arterioles	20
2	Cardiac lesion associated with pulmonary hypertension.....	36
3	Echocardiographic findings in PPHN.....	38
4	Non invasive estimation of PAP from Echocardiographic parameters.....	39
5	Intimal remodeling.....	44
6	Medial remodeling.....	45
7	Clinical finding at various met hemoglobin concentration...	69
8	Contraindication of ECMO.....	71
9	Cardiovascular effects of sildenafil.....	81 - 82
10	Mean Age & gestational age in our study groups.....	101
11	Manifestation of PPHN between the study group.....	102
12	Mean of associated PDA & treatment of PDA between the study groups.....	103
13	EPAP in our study groups.....	105
14	Duration to improvement of Sao2 & ABG by days in our study groups.....	106

List of Figures

No.	Title	Page
1	Formation of cardiac loop Aortic arches.....	4
2	Aortic arches.....	5
3	Development of the conotruncal ridges.....	6
4	Pulmonary artery and vein.....	8
5	Diagram of the alveoli with both cross-section and external view.....	9
6	Vascular supply to the lung.....	9
7	Pulmonary and bronchial circulation.....	11
8	Fetal circulation.....	15
9	Fetal circulation and oxygen saturation.....	17
10	Post natal changes in fetal circulation.....	19
11	Post natal changes in pulmonary vascular resistance.....	20
12	Change in pulmonary artery pressure, pulmonary blood flow and PVR, during the 7 weeks before birth, at birth and in the 7 weeks after birth.....	21
13	Pressure pulse contours in the right ventricle, pulmonary artery and aorta.....	23
14	Pressure in the different vessels of the lungs S. systolic; M, mean; D, diastolic.....	23
15	Histopathologic feature of pulmonary hypertension.....	40
16	Histologically, blood vessels consist of concentric layers.....	40
17	Pathobiology of PH.....	41

18	Schematic representation of the potential culture mechanisms involved in hypoxic-induced remodeling of a non muscular pulmonary artery.....	43
19	Mechanism of PH induced by loss of BMPR-2.....	47
20	Generation and action of endothelin-1.....	62
21	Various substances that decrease PVR.....	65
22	Metabolism of endogenous nitric oxide in the lung.....	67
23	ECMO circuit diagram.....	75
24	Mechanism of vasodilatory and anti proliferate effects of sildenafil.....	78
25	Estimation of systolic pulmonary artery pressure	90
26	Measurement of peak velocity of TR	94
27	Gender distribution in sildenafil group.....	100
28	Gender distribution in MgSo4 group.....	100
29	Mode of delivery between the study groups.....	101
30	Treatment of associated PDA between the study groups.....	103
31, 32	Mean EPAP values over the study period between the study groups.....	104
33	Duration to improvement of Sao2 (by days) between the study groups.....	105
34	Duration to improvement of ABG (by days) between the study groups.....	106
35	Outcome between the study groups.....	107

List of Abbreviation

AaDo2	: Alveolar- to arterial oxygen gradient
ABG	: Arterial Blood gases
ACD	: Alveolar Capillaries dysplasia
AMP	: Adenosine monophosphate
ANP	: A – type natriuretic peptide
AVMS	: Arterio- venous malformations
BMP	: Bone morphogenic protein
BMPR II	: Bone morphogenic protein receptor II
BNP	: B- type natriuretic peptide
CAM	: Congenital adenomatoid malformation
CAMP	: Cyclic adenosine monophosphate
CBC	: Complete Blood count
CDH	: Congenital Diaphragmatic hernia
CGMP	: Cyclic guanosine mono phosphate
CS	: Cesarean section
CVP	: Central venous pressure
ECMO	: Extra-corporeal membrane oxygenation
ETA	: Endothelin receptor A
ET-1	: Endothelin -1
ETB	: Endothelin receptor B
FIO2	: Inspired oxygen concentration
GMP	: Guanosine mono phosphate
GC	: Guanylate cyclase
INO	: Inhaled nitric oxide
IP3	: Inositol triphosphate
IVC	: Inferior vena cava

LA	: Left atrium
LV	: Left ventricle
LVO	: Left ventricular out put
MAP	: Mean air way pressure
MAS	: Meconium aspiration syndrome.
MPAP	: Mean pulmonary artery pressure
No	: Nitric oxide
NOS	: Nitric oxide synthetase
NSAID	: Non steroidal Anti-inflammatory drug
OI	: Oxygenation index
PA	: Pulmonary artery
PAP	: Pulmonary artery pressure
PAPs	: Pulmonary artery systolic pressure
Pao2	: Partial pressure of arterial oxygen
PDA	: Patent ductus arterious
PDE5	: Phospho diesterase 5
PEDP	: Pulmonary End diastolic pressure
PFC	: Persistent Fetal circulation
PFO	: Persistent foramen oval
PGI2	: Prostacyclin
PIP	: Peak inspiratory pressure
PKA	: CAMP- dependend protein Kinase
PKC	: Protein Kinase C
PKG	: CGMP – dependend protein kinase
PPHN	: Persistent pulmonary hypertension of newborn
PPM	: Part per million
PVR	: Pulmonary vascular resistance
RA	: Right atrium
RDS	: Respiratory distress syndrome

RV	: Right ventricle
RPEP	: Right ventricle pre- ejection period
RVO	: Right ventricular out put
RVET	: Right ventricular ejection time
Sao2	: Oxygen saturation
SERT	: Serotonin transporter
SGC	: Soluble guanyle cyclase
SMC	: Smooth muscle cell
SSRIs	: Selective serotonin reuptake inhibitors
SVC	: Superior vena cava
TGF-B	: Transforming growth factor-B
TPV	: Time to peak velocity
TR	: Tricuspid regurgitation
TTF-1	: Thyroid transcription factor 1
V-A	: Veno- arterial
VC	: Vasoconstriction
V-V	: Veno-venous
WBC	: White blood cell

INTRODUCTION

Persistent pulmonary hypertension in the newborn (PPHN) is a neonatal emergency due to the failure to achieve normal cardiopulmonary adaptation following delivery. PPHN still remains a challenging condition with high morbidity and mortality. (*Kleigman et al., 2007*)

The aim of treatment is to lower pulmonary vascular resistance, maintain systemic blood pressure, reverse right to left shunt, and improve arterial oxygen saturation. (*Abman et al., 2004*)

A variety of treatment include hyperventilation, pressor agents surfactant, sedation, Alkalinization, vasodilatation e.g (tolazoline, inhaled nitric oxide, Magnesium sulfate, Adenosine, sildenafil) and Extracorporeal membrane oxygenation ECMO (*Donn et al., 2007*).

PPHN can occur as a primary condition or be secondary to meconium aspiration, respiratory distress syndrome, infection or congenital diaphragmatic hernia (*Finer 2004*).

PPHN occurs in approximately 1.9 per 1000 new born and may be more frequent in developing countries. There is strong evidence for the use of inhaled nitric oxide (INO) and ECMO in the treatment of PPHN. However, many developing countries do not have access or the technical expertise required for these expensive therapies (*Chambers et al., 2006*).

MgSO₄ is a natural Ca channel blocker that antagonizes Ca ion entry into smooth muscle cell thus promoting vasodilatation. MgSO₄ is a safe and cheaper alternative for 1st line treatment in moderate PPHN and was chosen to be alternative therapy for PPHN when other conventional treatments fail, are contraindicated or are not available (*Chandran, 2004*).

Sildenafil is a potent and selective inhibitor of cGMP-specific PDE5. This isoenzyme metabolizes cGMP which is the Second-Messenger of NO and a principle mediator of smooth muscle relaxation and vasodilatation. By inhibiting the hydrolytic breakdown of CGMP, sildenafil prolongs the action of CGMP. This results in augmented smooth muscle relaxation and cause pulmonary vasodilatation. **(Reffermann and Kloner, 2003)**. Inhibition of PDE5 lead to increase the concentration of cyclic-AMP and GMP locally, which in turn leads to relaxation of pulmonary vasculature smooth muscles so sildenafil decreases pulmonary vascular resistance in pulmonary hypertensive neonate.**(Humbert,2004)**

AIM OF THE WORK

The aim of this study was to compare the use of sildenafil versus magnesium sulfate as pulmonary vasodilator in the treatment of persistent pulmonary hypertension of the newborn in addition to the conventional therapy in these newborn. Duration to improvement, degree of improvement, side effects and outcome were compared.

EMBRYOLOGICAL DEVELOPMENT OF PULMONARY ARTERIAL VASCULATURE:-

Development of pulmonary arteries:

The vascular supply to lung buds arises from the paired sixth aortic arches, which arises from truncus arteriosus, the upper end of bulbus cordis, as it represents the most cranial part of heart tube.

The paired sixth aortic arches give off branches to developing lung each one divides into ventral (medial) & dorsal (lateral) segment. The ventral segment of the right 6th aortic arch forms the proximal part of the right pulmonary artery which enters the right lung bud while its dorsal segment disappear (loses its connection within dorsal aorta). The ventral segment of the left 6th aortic arch forms the main pulmonary artery and the proximal part of left hilar branches which enters the left lung bud while the dorsal segment persists during the intrauterine life forming the ductus arteriosus which forms a connection between the left pulmonary artery and the arch of the aorta. The aortic arches connect the aortic sac ventrally with the 2 dorsal aorta dorsally which fuses together form common dorsal aorta. (*Risau et al., 1990*).




Figure (1): Formation of cardiac loop

A: 22 days, B; 23 day, C: 24 day

Broken Line: pericardium

(Sadler, 2004)




Fig (2):-A. Aortic arches and dorsal aortae before transformation into the definitive vascular pattern. B. Aortic arches and dorsal aortae after the transformation .Broken lines, obliterated components. Note the patent ductus arteriosus and position of the seventh intersegmental artery on the left C.The great arteries in the adult. Compare the distance between the place of origin of the left common carotid artery and the left subclavian in B and C. After disappearance of the distal part of the sixth aortic arch (the fifth arches never form completely), the right recurrent laryngeal nerve hooks around the right subclavian artery. On the left the nerve remains in place and hooks around the ligamentum arteriosum (Sadler, 2004).

Besides the different origin of pulmonary artery segment, two other processes probably contribute to the development of lung vasculature: Angiogenesis and vasculogenesis (*Morin and stermark, 1995*).

Course of Pulmonary artery in relation to Aorta:

Two ridges called the right & left major bulbar cushions develop inside the distal part of bulbus cordis & descend in the direction of ventricle following a spiral course. Later they fuse together forming aortico-pulmonary septum. The distal part of bulbus cordis become